- Previous Close
2,975.00 - Open
2,934.00 - Bid 2,901.00 x --
- Ask 2,924.00 x --
- Day's Range
2,891.00 - 2,951.00 - 52 Week Range
2,592.00 - 3,125.00 - Volume
87,600 - Avg. Volume
80,662 - Market Cap (intraday)
113.899B - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
18.73 - EPS (TTM)
155.93 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield 100.00 (3.42%)
- Ex-Dividend Date Mar 28, 2025
- 1y Target Est
2,900.00
BML, Inc. provides laboratory testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; special laboratory test, including RIA, cellular, immunological, and DNA analysis; and microbiological tests for medical and pharmaceutical societies and organizations; laboratory tests in tumorology, infectious disease, diabetes, hypertension, allergy, and genetic studies, as well as develops Frontier and Symphony automation systems, which automate pre-processing procedures from sorting to dispensing, and subsequent test procedures. It also provides medical information system services, which include electronic medical charts for networking medical information, as well as preventive medicine services. In addition, the company offers food sanitation test, including food sanitation control and food processing services, which comprise contract services for microorganism testing of raw materials, and prepared and processed food; environmental hygiene testing of food processing facilities and kitchens; and microorganism testing services, as well as assesses genetically modified organisms. Further, it provides drinking water and wastewater tests; work environment services, such as measurement of ethylene oxide gas, formaldehyde, organic solvent, and dust; environmental monitoring, which include measurement of indoor contaminants and other indoor environmental variables; and biological dioxin monitoring services. Additionally, the company offers analysis services for residual agricultural chemicals; dental test services for dental caries and periodontal diseases; consulting services for the approval of pharmaceuticals; investigative analysis services to pharmaceutical manufacturers; human genome analysis services; and gene expression analysis and testing for genes that cause susceptibility to infectious diseases. The company was incorporated in 1955 and is headquartered in Tokyo, Japan.
www.bml.co.jp4,513
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: 4694.T
View MorePerformance Overview: 4694.T
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4694.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4694.T
View MoreValuation Measures
Market Cap
113.90B
Enterprise Value
45.05B
Trailing P/E
18.72
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.81
Price/Book (mrq)
0.89
Enterprise Value/Revenue
0.32
Enterprise Value/EBITDA
4.59
Financial Highlights
Profitability and Income Statement
Profit Margin
4.30%
Return on Assets (ttm)
3.51%
Return on Equity (ttm)
4.87%
Revenue (ttm)
141.33B
Net Income Avi to Common (ttm)
6.08B
Diluted EPS (ttm)
155.93
Balance Sheet and Cash Flow
Total Cash (mrq)
66.42B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--